Schizophrenia and Recovery Program, The Royal Ottawa Mental Health Centre, Ottawa, ON, K1Z 7K4 Canada. EMAIL:
Ann Clin Psychiatry. 2021 Feb;33(1):45-52. doi: 10.12788/acp.0015.
Adjunctive psychostimulants have been proposed as a potential treatment option for the management of cognitive and/or negative symptoms of schizophrenia.
The present study is a retrospective review of use of adjunctive psychostimulants among outpatients enrolled in our tertiary Schizophrenia Program between 2014 and 2019. We assessed response to treatment, adverse effects, and the impact of various clinical factors on treatment outcome.
Of the 77 (out of 1,300) participants prescribed psychostimulants during the study period, 42.22% had chart-based evidence of significant improvement, 27.77% had minimal improvement, and 25.55% reported no change. The majority (61.9%) demonstrated improvement in attention, concentration, and/or other cognitive symptoms. Approximately one-third of cases had evidence of emergence of psychosis. Of the factors assessed, comorbid attention-deficit/hyperactivity disorder was associated with an increased likelihood of response, and higher doses of stimulants were associated with likelihood of emergence of psychosis.
Adjunctive psychostimulants could be a potential treatment consideration to address cognitive deficits in selected patients with schizophrenia.
辅助性精神兴奋剂已被提议作为治疗精神分裂症认知和/或阴性症状的潜在选择。
本研究是对 2014 年至 2019 年间参加我们三级精神分裂症项目的门诊患者使用辅助性精神兴奋剂的回顾性分析。我们评估了治疗反应、不良反应以及各种临床因素对治疗结果的影响。
在研究期间，77 名（1300 名中的 42.22%）接受精神兴奋剂治疗的参与者有图表证据表明病情显著改善，27.77%有轻度改善，25.55%报告无变化。大多数（61.9%）的注意力、集中力和/或其他认知症状得到改善。大约三分之一的病例出现了精神病发作的证据。在所评估的因素中，合并注意力缺陷/多动障碍与增加反应的可能性相关，而兴奋剂的较高剂量与精神病发作的可能性相关。
辅助性精神兴奋剂可能是治疗特定精神分裂症患者认知缺陷的潜在选择。
